Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes

被引：13

作者：

Inagaki, Nobuya ^{[2
]}

Ueki, Kohjiro ^{[3
]}

Yamamura, Ayuko ^{[1
]}

Saito, Hitoshi ^{[1
]}

Imaoka, Takeshi ^{[1
]}

机构：

[1] Eli Lilly Japan KK, Lilly Res Labs Japan, Kobe, Hyogo, Japan

[2] Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Kyoto, Japan

[3] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan

来源：

JOURNAL OF DIABETES INVESTIGATION | 2011年 / 2卷 / 06期

关键词：

Exenatide; Japan; Type 2 diabetes mellitus; CARDIOVASCULAR RISK-FACTORS; ACUTE-PANCREATITIS; GLYCEMIC CONTROL; HEPATIC BIOMARKERS; TREATED PATIENTS; INTERIM ANALYSIS; METFORMIN; EXENDIN-4; SULFONYLUREA; OBESITY;

D O I：

10.1111/j.2040-1124.2011.00137.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims/Introduction: We assessed the long-term (52 weeks) safety and efficacy of exenatide b.i.d. in Japanese patients with type 2 diabetes and suboptimal glycemic control.

引用

页码：448 / 456

页数：9

共 30 条

[1]

[Anonymous], 2006, Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation

[2]

Bergenstal RM, 2010, AM J MED, V123, P374

[3] Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes [J].

Blonde, L. ;

Klein, E. J. ;

Han, J. ;

Zhang, B. ;

Mac, S. M. ;

Poon, T. H. ;

Taylor, K. L. ;

Trautmann, M. E. ;

Kim, D. D. ;

Kendall, D. M. .

DIABETES OBESITY & METABOLISM, 2006, 8 (04) :436-447

[4] One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial [J].

Bunck, Mathijs C. ;

Diamant, Michaela ;

Corner, Anja ;

Eliasson, Bjorn ;

Malloy, Jaret L. ;

Shaginian, Rimma M. ;

Deng, Wei ;

Kendall, David M. ;

Taskinen, Marja-Riitta ;

Smith, Ulf ;

Yki-Jarvinen, Hannele ;

Heine, Robert J. .

DIABETES CARE, 2009, 32 (05) :762-768

[5] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [J].

Buse, JB ;

Henry, RR ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2004, 27 (11) :2628-2635

[6] Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials [J].

Buse, John B. ;

Klonoff, David C. ;

Nielsen, Loretta L. ;

Guan, Xuesong ;

Bowlus, Christopher L. ;

Holcombe, John H. ;

Maggs, David G. ;

Wintle, Matthew E. .

CLINICAL THERAPEUTICS, 2007, 29 (01) :139-153

[7] One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice [J].

Buysschaert, M. ;

Preumont, V. ;

Oriot, P. R. ;

Paris, I. ;

Ponchon, M. ;

Scarniere, D. ;

Selvais, P. .

DIABETES & METABOLISM, 2010, 36 (05) :381-388

[8] Oral antihyperglycemic therapy for type 2 diabetes mellitus [J].

Cheng, AYY ;

Fantus, IG .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (02) :213-226

[9] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J].

DeFronzo, RA ;

Ratner, RE ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2005, 28 (05) :1092-1100

[10] A cohort study of acute pancreatitis in relation to exenatide use [J].

Dore, D. D. ;

Bloomgren, G. L. ;

Wenten, M. ;

Hoffman, C. ;

Clifford, C. R. ;

Quinn, S. G. ;

Braun, D. K. ;

Noel, R. A. ;

Seeger, J. D. .

DIABETES OBESITY & METABOLISM, 2011, 13 (06) :559-566

← 1 2 3 →